2 hours ago
AstraZeneca (AZN) Stock Plunges 9% as Wainua Trial Misses Primary Endpoint
AstraZeneca (AZN) stock fell 9% after Wainua missed its ATTR-CM trial endpoint. Design flaws cited while Ionis dropped 13.8% and Alnylam jumped 17%.
The post AstraZeneca (AZN) Stock Plunges 9% as Wainua Trial Misses Primary Endpoint appeared first on Blockonomi.
Source: Blockonomi →Related News
- 38 minutes ago
Tesla (TSLA) Stock Slides 12% YTD as Analyst Warns on Robotaxi Timeline
- 39 minutes ago
AeroVironment (AVAV) Shares Tumble 6% Following RBC Downgrade to Sector Perform
- 40 minutes ago
SpaceX (SPCX) Stock Soars on Wall Street Optimism: Can It Reach $900?
- 41 minutes ago
Advanced Micro Devices (AMD) Stock Rallies on Fresh Analyst Coverage and Upgrade...
- 42 minutes ago
Honeywell (HON) Stock Rises After EPS Guidance Update — Here’s What Actually Cha...